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Background: Novel effective anti-influenza agent that tolerates influenza virus antigenic variation is needed. Highly
conserved influenza virus M2 protein has multiple pivotal functions including ion channel activity for vRNP
uncoating, anti-autophagy and virus assembly, morphogenesis and release. Thus, M2 is an attractive target of anti-
influenza agents including small molecular drugs and specific antibodies.
Methods: Fully human monoclonal single chain antibodies (HuScFv) specific to recombinant and native M2
proteins of A/H5N1 virus were produced from huscfv-phagemid transformed E. coli clones selected from a HuScFv
phage display library using recombinant M2 of clade 1 A/H5N1 as panning antigen. The HuScFv were tested
for their ability to inhibit replication of A/H5N1 of both homologous and heterologous clades. M2 domains
bound by HuScFv of individual E. coli clones were identified by phage mimotope searching and computerized
molecular docking.
Results: HuScFv derived from four huscfv-phagemid transformed E. coli clones (no. 2, 19, 23 and 27) showed
different amino acid sequences particularly at the CDRs. Cells infected with A/H5N1 influenza viruses (both
adamantane sensitive and resistant) that had been exposed to the HuScFv had reduced virus release and
intracellular virus. Phage peptide mimotope search and multiple alignments revealed that conformational epitopes
of HuScFv2 located at the residues important for ion channel activity, anti-autophagy and M1 binding; epitopic
residues of HuScFv19 located at the M2 amphipathic helix and cytoplasmic tail important for anti-autophagy, virus
assembly, morphogenesis and release; epitope of HuScFv23 involved residues important for the M2 activities similar
to HuScFv2 and also amphipathic helix residues for viral budding and release while HuScFv27 epitope spanned
ectodomain, ion channel and anti-autophagy residues. Results of computerized homology modelling and molecular
docking conformed to the epitope identification by phages.
Conclusions: HuScFv that bound to highly conserved epitopes across influenza A subtypes and human pathogenic
H5N1clades located on different functional domains of M2 were produced. The HuScFv reduced viral release and
intracellular virus of infected cells. While the molecular mechanisms of the HuScFv await experimental validation,
the small human antibody fragments have high potential for developing further as a safe, novel and mutation
tolerable anti-influenza agent especially against drug resistant variants.
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Influenza virus matrix-2 (M2) is a type III transmem-
brane protein of a class IA viroporin family [1]. Each M2
molecule comprises different domains: N-terminal ecto-
domain (M2e; 25 residues; 1–25), transmembrane
domain (21 residues; 26–46), amphipathic helix (16 resi-
dues; 47–62) and C-terminal (35 residues; 63–97) [2,3].
M2 homotetrameric molecules are present on infected
cell surface (~ two M2 tetramers per one HA trimer)
and virion (~23-60 M2 tetramers per a virion) [4,5]. At
the early phase of infection, the protein functions as a
pH-activated ion channel allowing protons to enter the
virion causing release of the vRNPs from the endosome
into cytoplasm for further replication in nucleus [6].
Consequently, M2 prevents acid-induced conformational
change of the newly synthesized hemagglutinin mo-
lecules that are cleaved in trans-Golgi network [7].
Recently, M2 was found to block fusion of autophago-
somes to lysosomes and inhibit autophagy causing accu-
mulation of the autophagosomes which compromised
virus infected cell survival [8]. At the late replication
process, M2 is recruited by M1 to the site of virus bud-
ding for virion assembly and morphogenesis [3]. There-
after, M2 amphipathic helix alters membrane curvature
at the neck of the budding virion causing membrane
scission and the virus release [3]. Because of the multiple
pivotal functions in the influenza virus infectious cycle,
M2 has been an attractive target of anti-influenza agents.
Presently, there are two families of anti-influenza
drugs: adamantanes that inhibit M2 ion channel activity
and neuraminidase inhibitors [9]. These drugs must be
taken at the early phase of infection for high therapeutic
effectiveness [10]. Drug resistant virus mutants have
emerged continuously causing treatment failure [11].
Adamantane frequently causes side effect on the central
nervous system [12]. There is a need of novel anti-
influenza agent that is safe and more tolerable to the
virus mutations than the currently available drugs.
Antibodies have been used with success for influenza
treatment [13-19]. Convalescing plasma could rescue pa-
tient infected with drug escape H5N1 virus mutant [17].
Human ScFv specific to H5 could protect mice from le-
thal challenges with H5N1 viruses of both clades 1 and
2 [18]. Passively transferred M2e-specific monoclonal
antibody to mice caused acceleration of the lung viral
clearance [19]. Antibody is more tolerable to mutation
of the viral target than small molecular drugs [20]. Thus
in this study, monoclonal single chain antibody frag-
ments (HuScFv) which are fully human proteins and
bound specifically to recombinant and native M2 pro-
teins of H5N1 viruses were produced. The HuScFv in-
terfered with the virus replication. Presumptive epitopes
of the effective HuScFv on the M2 monomer were iden-
tified by means of phage mimotopic peptide searching andmultiple alignments. Homology modelling and molecular
docking were used to predict the regions and residues of
the tetrameric M2 ion channel bound by the small anti-
bodies in order to predict the molecular mechanisms
of the antibody in mediating inhibition of the virus
replication.
Results
M2 specific HuScFv and characteristics
Recombinant M2 (rM2) of A/duck/Thailand/144/2005
(H5N1) (clade 1) was successfully purified from lysate of
transformed E. coli carrying pET-20b(+) vector with full
length M2 cDNA insert. The protein was verified by
SDS-PAGE and Western blotting (Figure 1). The de-
duced amino acid sequence of the cloned M2 showed
100% homology to the M2 sequences of various H5N1
isolates (data not shown) [21].
The recombinant M2 (rM2) was used as antigen in sin-
gle round phage panning for selecting the antigen bound
phage clones. After infecting HB2151 E. coli with the rM2
bound-phages, 30 E. coli clones were randomly selected
and screened for the presence of gene sequence coding
for HuScFv (huscfv) and 27 clones (90%) were positive
(Figure 2A). Among the huscfv positive E. coli clones, 17
clones could express HuScFv (57%) as determined by
Western blotting. Figure 2B shows Western blot patterns
of HuScFv in lysates of 7 representative huscfv positive E.
coli clones. HuScFv in lysates of 10/17 E. coli clones (no.
2, 5, 9, 13, 14, 19, 20, 23, 27 and 29) gave significant bind-
ing to the rM2 by indirect ELISA (Figure 3A). They also
bound to native M2 (nM2) in homogenate of clade 2 A/
H5N1 (A/chicken/Thailand/NP-172/2006) infected cells
by Western blotting (data not shown). The huscfv se-
quences of the 10 E. coli clones showed 6 different DNA
banding patterns after MvaI digestion, 14% SDS-PAGE
and ethidium bromide staining (Figure 3B). Clones no. 5
and 20 had pattern 2 (lane 2); clones no. 9 and 14 had pat-
tern 3 (lane 3), clones no. 13 and 23 had pattern 5 (lane 5)
and clones no. 2, 19 and 27 had patterns 1, 4 and 6, re-
spectively (lanes 1, 4 and 6). Western blot analysis showed
that HuScFv of clones no. 2, 19, 23 and 27 bound to rM2
and nM2 (Figure 3C and 3D, respectively). They also
bound to nM2 in the virus infected cells as tested by
immunfluorescence assay (Additional file 1: Figure S1).
Deduced amino acid sequences of huscfv of the four
clones showed high diversity especially at the complemen-
tarity determining regions (CDRs 1–3) of both VH and
VL chains (data not shown) indicating their different epi-
tope specificities.
M2 specific-HuScFv mediated interference of the
influenza virus replication
Figure 4A shows numbers of virus foci in MDCK cells
infected directly with adamantane sensitive and resistant
Figure 1 SDS-PAGE and Western blot patterns of recombinant
M2 protein. Lane M: protein molecular weight marker; lanes 1 and
2: SDS-PAGE patterns of the soluble rM2 and refolded rM2 from
E. coli inclusion, respectively. Soluble rM2 appears as a band of
17 kDa while M2 prepared from the E. coli inclusion appears as a
protein doublet which the lower band is mature rM2 and the upper
band is rM2 linked with pelB1 leader peptide of pET20b(+) (21 kDa).
Lanes 3 and 4: Western blot patterns of the soluble rM2 and
pelB1-linked M2, respectively. For the Western blotting, strips of
nitrocellulose membrane (NC) blotted with SDS-PAGE separated-rM2
were incubated with mouse anti-6x-histidine antibody, goat anti-
mouse immunoglobulin-alkaline phosphatase conjugate and BCIP/
NBT substrate, respective. Uppermost band in lane 4 (arrow) is rM2
dimer. Numbers at the left are relative molecular masses (Mr)
of proteins.
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2 and A/dog/Thailand/KU-08/2004 (H5N1) clade 1, re-
spectively] and the cells were grown in medium
containing HuScFv, PAb, rimantadine or medium alone
for 15 h (see experiment 1 in Methods). No foci of the
rimantadine sensitive virus were found in the infected
cells cultured with HuScFv of clones no. 19 and 23 and
rimantadine while only few foci were seen
in cells exposed to HuScFv of clones no. 2 and 27 and
PAb. The numbers of amantadine-resistant virus foci ininfected cells cultured in HuScFv, PAb to M2 and ri-
mantadine supplemented medium were markedly re-
duced compared with the infected cell control. For
experiment 2 which the viruses had been exposed to M2
specific-HuScFv, PAb to M2, rimatadine or medium be-
fore adding to the cell monolayer and the infected cells
were cultured in the respective inhibitors or medium
alone, the adamantane sensitive virus foci were not
found in the cells exposed to all inhibitors. Numbers of
foci of the amantadine resistant virus treated with the
HuScFv, PAb to M2 and rimantadine were markedly re-
duced compared with the infected cell control (Figure 4B).
Additional file 2: Figure S2 shows appearances of the virus
foci in MDCK cells of Figure 4B.
Figure 5 shows qPCR results of M1 mRNA in culture
supernatants and inside the cells that had been infec-
ted with adamantane sensitive and resistant influenza
viruses, i.e., A/chicken/Thailand/NP172/2006 (H5N1)
(clade 2.3.4) and A/dog/Thailand/KU08/2004 (H5N1)
(clade 1), respectively. The viruses were added directly
to the cells (experiment 1) or mixed with HuScFv, PAb
to M2, rimantadine or medium alone before adding to
cells (experiment 2). After allowing cellular entry and re-
moving extracellular viruses, the infected cells were cul-
tured in the presence of HuScFv/PAb/rimantadine or
medium alone for 15 h. In Figure 5A, the amantadine
sensitive virus was used to infect the cells. From both
experiments, rimantadine was the best in reducing the
viral M1 mRNA amounts in both supernatants and in-
side the cells. The HuScFv of all clones and PAb could
reduce significantly the virus in both culture superna-
tants and inside the cells in comparison with the
infected cells (p < 0.05). In experiment 1 of drug resistant
virus (Figure 5B), rimantadine was less effective than the
HuScFv of clones no. 23 and 27 and PAb in reducing
the M1 mRNA in the culture supernatants and equally
effective to the HuScFv of clones 2 and 19. The effec-
tiveness in reducing intracellular virus, in increasing
order of magnitude, were HuScFv2 < HuScFv19 < ri-
mantadine < HuScFv27 = PAb < HuScFv23. For experi-
ment 2, the effectiveness of the inhibitors in reducing
the virus release were rimantadine = PAb < HuScFv2
< HuScFv27 < HuScFv23 < HuScFv19. For reduction of
intracellular virus, HuScFv of clones no. 19 and 27 were
most effective.
Phage peptides that bound to HuScFv (mimotopes),
HuScFv epitopes on M2 and validation of the phage
mimotopes
Ten clones each of phages displaying 12 mer peptides
that bound to HuScFv- 2, -19, -23 and −27 were sequen-
ces (see Methods). All 10 clones that bound to HuScFv2
revealed identical peptide sequence (ELWPPNPHAGPP)
designated mimotope type M2-1. There was also one
AB
Figure 2 E. coli clones carrying huscfv and HuScFv in their lysates revealed by Western blot analysis. (A) Lane M: One kb DNA ladder;
lanes 2, 4–10 and 12–30: amplicons of huscfv in E. coli clones 2, 4–10 and 12–30, respectively; lane neg, negative control which was PCR result of
PCR Master mix without DNA template. Numbers at the left of both blocks are DNA sizes in base pairs (bp). (B) Western blot results for detecting
HuScFv in lysates of 8 representative huscfv positive clones. Lane M: protein standard marker; lanes 1–6 and 8: positive HuScFv (~27 kDa) in
lysates of huscfv positive E. coli clones; lane 7: lysate of huscfv positive E. coli that did not express HuScFv. Numbers at the left are relative
molecular masses (Mr) of proteins.
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HuScFv19. HuScFv23 had three mimotope types: M23-1
(ALWPPNLHAWVP), M23-2 (QYALWPPNLQAGVP)
and M23-3 (HSNWDMPPIRLVAS). Two mimotope types
were deduced from 10 HuScFv27 bound phage clones:
M27-1 (EDVDEIHNQSHP) and M27-2 (ALWPPNLH
AWVP). Sequences of all mimotope types were aligned
with the monomeric M2 sequences of A/H5N1 of the
database, i.e., clade 1: AY651385.1 and clade 2: AB47
8035.1, in order to locate tentative regions and residues
on the M2 bound by the HuScFv (epitopes) (Figure 6).
The 12 residue phage mimotope peptide of HuScFv of
clone no. 2 (M2-1) matched with 39ILWILD44 in trans-
membrane domain and 63P-TAGVP69 in cytoplasmic do-
main of M2 of both clades. The mimotope M19-1
matched with 51IYRRLKYG58 of amphipathic helix and74EEYR77 of cytoplasmic domain. The M23-1 matched
with residues 39ILWILD44 of transmembrane helix and
59LK60 of amphipathic helix and 66AGVP69 of cytoplas-
mic doamin; M23-2 matched with 37HLILWILD44 of
transmembrane helix, 59LK60 of amphipathic helix and
66AGVP69 of cytoplasmic domain and M23-3 matched
with 38LILWILDR45 of transmembrane helix, 59LK60
of amphipathic helix and 67GVPE70 of cytoplasmic
domain. The mimotope M27-1 matched with 5TEVE8
and 18RCSDSSDP25 in ectodomain and M27-2:
matched with 21DSSDP26 in ectodomain and
37HLILWIL43 in transmembrane helix.
Competitive ELISA for determining the ability of the
phage mimotopes and irrelevant phage mimotope in
inhibiting the HuScFv binding to the rM2 are shown in
Figure 7. Binding of the HuScFv clones no. 2, 19, 23,
AB C D
Figure 3 Characterization of the selected phagemid transformed-HB2151 E. coli clones. (A) Indirect ELISA results showing the binding of
HuScFv in lysates of 17 huscfv positive E. coli clones to rM2 and BSA control. HuScFv of 10 clones (no. 2, 5, 9, 13, 14, 19, 20, 23, 27 and 29) bound
specifically to the rM2. (B) RFLP of huscfv sequences of the 10 ELISA positive clones showed 6 different DNA patterns. Lanes 1–6: RFLP of clones
2, 5, 14, 19, 23 and 27, respectively. (C) Western blot patterns of HuScFv-2, -19, -23 and −27 that bound to rM2; HuScFv-5 and −14 did not bind
to the rM2 (data not shown). Lane M: protein molecular weight standard; lane 1: positive control (rM2 blotted strip was probed with mouse PAb
to rM2); lane 2: negative control (rM2 blot was probed with lysate of normal E. coli); lanes 3–6, rM2 blotted strips probed with HuScFv-2, -19, -23,
and −27, respectively. The antigen-antibody reactive bands were revealed by using mouse anti-E tag-enzyme conjugate and substrate. (D)
Western blot results for determining the binding of HuScFv of clones 2, 19, 23 and 27 to nM2. Lane M: protein molecular weight standard; lane 1:
positive control which the SDS-PAGE separated rM2 purified from the E. coli lysate was probed with mouse PAb to rM2; lane 2: positive control
which SDS-PAGE separated H5N1 virus lysate containing nM2 was probed with mouse PAb to rM2; lanes 3–6, nM2 blotted strips probed with
HuScFv of clones no. 2, 19, 23, and 27, respectively; the antigen-antibody reactive bands were detected by mouse anti-6x His tag; lane 7: negative
control which the nM2 blotted strip was probed with lysate of normal E. coli. Numbers at the left of (C) and (D) are relative molecular masses
(Mr) of proteins.
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mimotope types. The percent inhibition was not 100%
for all HuScFv due to binding of the phage peptides to
only partial regions of M2. Nevertheless, the results indi-
cated that the mimotopes carried the amino acid resi-
dues analogous to the native M2 which verified the
mimotope search data.
Computerized binding between HuScFv and tetra-
meric M2 ion channel are shown in Figure 8. The
RDOCK and interactive M2 residues for all HuScFv are
shown in Figure 8A. The RDOCK between the HuScFv2
and the tetrameric M2 ion channel was −30.38; the
HuScFv2 bound to residues 38LIL-ILDRLF47 of the first
monomer, residues 25P-–A–II-IL–ILW-LD44 of the
third monomer and residues 31NIIGILHLILWIL-RL-
F48 of the fourth monomer. The RDOCK betweenHuScFv19 and the M2 tetramer was also −30.48; the
HuScFv19 bound to 25PI-–AA-II–L–IL–L–LF48 of the
first monomer and 31NI-–IL-LILWIL-RLFF49 of the
second monomer. The RDOCK between the HuScFv23
and the M2 tetramer was −21.99; the HuScFv23
bound to residues 24DPI-VAA-II–L–L——L44 of the
third monomer and 28V--NI–IL-LILWIL-RLFF49 of the
fourth monomer. The RDOCK between the HuScFv27
and the M2 tetramer was −27.92; the HuScFv27 bound
to residues 25PI-VAA-II–LH-IL–L43 of the third mono-
mer and 31N-–LILWIL-LFFK50 of the fourth monomer.
Regions of individual monomers of the tetrameric M2
ion channel template obtained from PDB entry 2LY0
that interacted with the HuScFv-2, -19, -23 and −27
were obtained from computerized molecular docking as
shown in Figure 8B. The so-obtained structure of this
AB
Figure 4 Numbers of virus foci in the MDCK cells infected with
adamantane sensitive and resistant viruses. Figure 4A show
results of experiment 1 which the viruses were added directly to the
MDCK cell monolayer and the infected cells were cultured in the
medium containing HuScFv, PAb to M2, rimantadine or medium
alone for 15 h. No foci of the rimantadine sensitive virus were found
in the infected cells cultured with HuScFv of clones no. 19 and 23
and rimantadine while only few foci were seen in cells exposed to
HuScFv of clones no. 2 and 27 and PAb. The numbers of
amantadine-resistant virus foci in infected cells cultured in HuScFv,
PAb to M2 and rimantadine supplemented medium were markedly
reduced compared with the infected cell control. Figure 4B shows
results of experiment 2 which the viruses had been exposed to M2
specific-HuScFv, PAb to M2, rimatadine or medium before adding to
the cell monolayer and the infected cells were cultured in the
respective inhibitors or medium alone, the adamantane sensitive
virus foci were not found in the cells exposed to all inhibitors.
Numbers of foci of the amantadine resistant virus treated with the
HuScFv, PAb to M2 and rimantadine were markedly reduced
compared with the infected cell control.
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complete transmembrane helix and 3 residues of amphi-
pathic helix but lacks completely the C-terminal residues.
Multiple alignments of M2 amino acid sequences of
various influenza viruses
Influenza A viruses belonging to different subtypes and
human infected H5N1 clades revealed highly conservedM2 sequences especially at the HuScFv binding sites
(Additional file 3: Figure S3).
Discussions
The surface exposed M2 protein of influenza viruses has
several pivotal functions in the virus infectious cycle.
Therefore, the protein has been attractive target of anti-
influenza agents. In this study, fully human single chain
antibody variable fragments (HuScFv) that bound specif-
ically to recombinant and native M2 of A/H5N1 viruses
belonging to different clades were successfully produced
using phage display technology. The so-produced small
antibodies were tested for their ability to inhibit the
virus replication using rimantadine and polyclonal anti-
bodies to full length recombinant M2 (PAb) as positive
inhibitors. As expected, rimantadine was highly effective
for the drug sensitive virus variant and rather refractory
for the resistant mutant. The observed ability of the PAb
in reducing the viruses inside the cells and in cell culture
supernatant should be due to viral aggregation and steric
hindrance of the ion channel activity. The HuScFv de-
rived from all four E. coli clones also caused significant
reduction of the amounts of both drug sensitive and re-
sistant A/H5N1 viruses in the infected cells and the cul-
ture supernatants.
The first known M2 function is the pH dependent se-
lective proton channel activity formed by homotetrameic
M2 molecules on the virus surface. The channel is im-
portant for vRNP uncoating from endosome into cyto-
plasm and subsequent replication in nucleus [6]. The
ion channel pore is lined by the polar amino acids Val27,
Ser31, Gly34, His37, Trp41, Asp44 and Arg45 of the trans-
membrane (TM) tetrahelices while the channel integrity
is maintained by TM non-polar residues and the posi-
tively charged residues of the TM and the amphipathic
helix [22]. At the high pH, the pore is closed by the TM
helices and the constrictive gates mediated by Val27 at
the N-terminal ion entrance and Trp41 at the C-terminal
ion exit [2,22]. Under endosomal low pH condition, the
highly proton selective His37 senses the acidification at
the N-terminal and allows inward flow of H+ through
the channel, whereas the gate formed by linking the
Trp41 indole ring side chain with Asp44 and Arg45 is
open; thus allowing the outward flow of the proton
to the C-terminal and release [23]. Adamantane com-
pounds including amantadine and its derivative ri-
mantadine block the ion channel activity of influenza A
viruses. Amantadine obstructs the ion channel pore by
binding to Ser31 and the surrounding Val27, Ala30 and
Gly34 [24] while rimantadine binds to the gate at a lipid-
facing pocket of the channel formed by Trp41, Ile42, and
Arg45 from one TM helix and Leu40, Leu43, and Asp44 of
the nearby helix [2]. Resistance to the drugs has oc-





Figure 5 (See legend on next page.)
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Figure 5 Log2 of fold decrease in M1 mRNA in culture supernatants and inside the MDCK cells infected with amantadine
sensitive and resistant influenza viruses. Figure 5A and 5B show results of various inhibitors including HuScFv/rimantadine/PAb and
medium control on amantadine sensitive virus [A/chicken/Thailand/NP172/2006 (H5N1) (clade 2)] and resistant virus [A/dog/Thailand/
KU08/2004 (H5N1) (clade 1)], respectively.
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and less so V27A and L26F [25,26]. The mutations cause
failure of ion channel blocking by amantadine and inef-
fective fitting of rimantadine into the channel pocket
due to the weakness of the TM helix packing [27]. Se-
veral compounds that are potent inhibitors of V27A and
L26F mutants have been produced and tested [28]. How-
ever, effective inhibitor of S31N mutant has not been
found [29].
It is known that during various virus infections, such
as hepatitis C, human immunodeficiency, polio, toga and
influenza, cellular membrane has increased permeability
[30-35]. Intracellular entry of HuScFv specific to influ-
enza virus protein and co-localization of the antibody
with the specific protein target inside the infected cells
have been observed by confocal microscopy (data not
shown). In this study, the monovalent HuScFv which
devoid of virus agglutinating ability were effective in
inhibiting the virus replication indicating that the small
antibodies could enter the virus infected cells and
exerted M2 function interference. Epitopes of the
HuScFv identified by means of phage mimotope sear-
ching and mimotope inhibition ELISA as well as mo-
lecular docking pointed out that the HuScFv of clonesFigure 6 Phage peptide sequences matched with residues of A/H5N1
mimotope type (M2-1: ELWPPNPHAGPP) matched with amino acid residue
viruses; HuScFv19 mimotope type (M19-1: VQIPLSYGQYYK) matched with re
HuScFv23 mimotope types (M23-1:ALWPPNLHAWVP, M23-2: QYALWPPNLQ
transmembrane domain, amphipathic helix and cytoplasmic C-terminal; mi
ALWPPNLHANVP) matched with M2 residues in ectodomain and transmemno. 2, 23, and 27 bound to the gate area (Trp41) of the
M2 ion channel. Therefore, the observed ability of the
HuScFv of these clones in inhibiting the influenza virus
replication was likely to be a consequence of the anti-
body mediated interference of the ion channel activity
leading to failure of the virus uncoating. Moreover, the
pH gradient equilibration between the trans-Golgi net-
work and cytosol by the ion channel activity could be
interrupted also, causing pre-mature maturation of the
virus hemagglutinin [7]. The amphipathic helix and
cytoplasmic domain of the influenza virus M2 induces
cellular membrane curvature during the virus assembly,
increases vRNP packaging by M1-M2 interaction and as-
sists the membrane scission in virus budding process
[3]. The finding that peptide epitopes of the HuScFv of
clones no. 2, 19 and 23 located in the amphipathic and
cytoplasmic domains of the M2 indicated that the anti-
bodies might inhibit the virus replication by interfering
with the functions of the amphipathic helix and the
cytoplasmic tail. During the infection, the N-terminal 1–
60 residues of the influenza virus M2 compromise sur-
vival of influenza virus-infected cells by inhibiting the
cellular macroautophagy formation [8]. The finding that
many epitopic residues of M2 potentially bound by themonomeric M2 molecule (epitopes of HuScFv). HuScFv2
s in transmembrane helix and cytoplasmic C-terminal of M2 of both
sidues of the M2 amphipathic helix and cytoplasmic C-terminal;
AGVP, M23-3: HSNWDNPPIRLVAS) matched with residues in
motope types of HuScFv27 (M27-: EDVDEIHNQSHP and M27-2:
brane helix.
Figure 7 Competitive ELISA for determining efficiencies of phage mimotopes in blocking the HuScFv binding to rM2. In the assay,
individual phage mimotope types, i.e., M2-1: ALWPPNLHAWVP, M19-1: VQIPLSYGQYYK, M23-1: HSNWDMPPIRLVAS, M23-2: QYALWPPNQAGVP, and
M23-3: HSNWDMPPIRLVAS, M27-1: EDVDEIHNQSHP and M27-2: ALWPPNLHAWVP at 104, 105 and 106 pfu were mixed with individual HuScFv
(5 μg) before adding to the ELISA well containing immobilized rM2 (10 μg). HuScFv mixed with irrelevant phage mimotope served as background
inhibition controls. The percent ELISA inhibition was calculated. The results indicated that the mimotopes could inhibit the HuScFv binding to rM2;
implying that they carried the amino acid residues analogous to the native M2 residues that could be bound by the respective HuScFv.
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tion indicating that the antibodies might as well counter-
act the M2 function on anti-autophagosome-lysosome
fusion. Multiple alignments of the M2 amino acid
sequences of various influenza A subtypes and human
pathogenic clades of subtype H5N1 revealed that the
HuScFv epitopic peptides are highly conserved implying
that the HuScFv should be able to counteract the M2 ac-
tivities across subtypes and H5N1 clades. Although the
speculated molecular mechanisms of the HuScFv pro-
duced in this study in interfering with the influenza virus
replication await experimental verification, the HuScFv
have high potential for developing further as a safe,
novel and mutation tolerable pan anti-influenza agent.Conclusions
Human monoclonal single chain antibody variable frag-
ments (HuScFv) that bound specifically to both recom-
binant and native M2 proteins of A/H5N1 influenza
viruses were produced by using phage display techno-
logy. HuScFv from four phagemid transformed E. coli
clones mediated replication inhibition of H5N1 influenza
viruses belonging to clades 1 and 2. Phage mimotope
searching and computerized homology modeling and
molecular docking revealed that the HuScFv of the four
bacterial clones reacted with different functional do-
mains of the influenza virus M2. The small human anti-
body fragments have high potential for developing
further as a safe, novel and mutation tolerable broad
spectrum anti-influenza agent.Methods
Influenza viruses
Influenza A virus strains used in this study are listed in
Table 1. They were propagated in 8–10 day old embryo-
nated chicken eggs. The allantoic fluids of all eggs were
collected, pooled, filtrated through 0.2 μM membrane
(Pall, USA) and kept in small aliquots at −80°C. Virus ti-
ters were determined by hemagglutination (HA) assay
against 1% chicken erythrocytes [36]. Optimal multipli-
city of infection (MOI) was calculated from titration of
50% tissue culture infected dose (TCID50) [36,37] in
Mardin-Darby canine kidney (MDCK) cells grown at
37°C under 5% CO2 atmosphere in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen, USA) supple-
mented with 2% heat inactivated fetal bovine serum
(FBS) (Hyclone, Thermo Scientific, USA), 2 mM L-
glutamine, penicillin (100 U/ml) and streptomycin (100
μg/ml).
Preparation of recombinant NP (rNP), recombinant M2
(rM2) and native M2 (nM2)
Coding sequences of NP (1,500 bp) and M2 (291 bp)
were PCR amplified from A/duck/Thailand/144/2005
cDNA by using specific primers [21]. Each amplicon was
cloned into pET-20b(+) vector (Novagen, USA) and in-
troduced into BL21 (DE3) E. coli. Selected transformed
E. coli clones were grown in LB medium containing 100
μg/ml ampicillin (LB-A) until the OD600nm was 0.5. The
E. coli cultures were induced with 0.5 mM IPTG to ex-
press the recombinant proteins. The bacterial lysates
containing 6x-his-tagged-NP and -M2 were purified (Ni-
AHuScFv-2     HuScFv-19    HuScFv-23      HuScFv-27
B
Figure 8 Residues and areas of individual monomers of tetrameric M2 ion channel interacted with the HuScFv. (A) Predicted M2
residues (black shades) in individual monomers of the ion channel which were bound by the HuScFv. (B) Results of molecular docking between
the HuScFv with the tetrameric M2 ion channel template which was obtained from PDB entry 2LY0. (I) Interaction of HuScFv-2 (green), -19
(cyan), -23 (violet) and −27 (blue) with tetrameric M2 ion channel template. The so-obtained template contained only six residues of ectodomain
(green), complete transmembrane helix (yellow) and 3 residues of amphipathic helix (pink) but lacked completely the C-terminal residues. (II)
Regions (red shades) of individual M2 monomers (colored in light blue, light pink, light brown and pale yellow for monomers 1–4, respectively)
that interacted with the HuScFv.
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binant preparation was verified by 14% SDS-PAGE and
Coomassie Brilliant Blue G-250 (CBB) staining, Western
blot analysis and LC-MS/MS and protein content was
determined.
MDCK cells infected for 24 h with mouse adapted A/
chicken/Thailand/NP172/2006 at MOI 1 were harvested,
washed with phosphate buffered saline, pH 7.4 (PBS)
and subjected to ultrasonic disintegration in the buffer
on ice. The homogenate was centrifuged and the super-
natant (lysate) containing nM2 was kept at −20°C until
use.Table 1 Influenza A/H5N1 viruses used in this study




nd, not determined; * adamantane resistant; **mouse adapted, adamantine sensitivPolyclonal antibodies (PAb) against rM2 and rNP
Animal experiments were approved by Veterinary
Science-Animal Care and Use Committee (FVS-AUCU),
Faculty of Veterinary Medicine, Kasetsart University,
Thailand. ICR mice were immunized with either rM2 or
rNP mixed with alum adjuvant [39]. Serum antibody ti-
ters against the homologous antigens were determined
by indirect ELISA. Western blot analysis was used for
determining antigenic specificities of the antibody prepa-
rations. Recombinant M2 and rNP were subjected to 14
and 12% SDS-PAGE, respectively. The separated compo-
nents were electroblotted onto nitrocellulose membranesost Reciprocal HA titer Reference/accession number
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with 5% skim milk in PBS and washed, the NC were in-
cubated with the mouse immune sera. Goat anti-mouse
immunoglobulin-alkaline phosphatase conjugate and
BCIP/NBT substrate were used for revealing the rM2/
rNP-antibody reactive bands at ~17 and 60 kDa,
respectively.
Production and characterization of M2-specific human
ScFv (HuScFv)
Phage clones displaying M2-bound HuScFv were se-
lected from a human ScFv phage display library cons-
tructed previously [40]. Phage display library was added
into an ELISA well coated with rM2. After incubation,
unbound phages were removed by extensive washing.
Log phase HB2151 E. coli suspension was added to the
well containing the rM2 bound phages. The bacteria
were spread on a selective agar plate and incubated
overnight. Colonies on the agar were picked randomly
and screened for the presence of HuScFv coding se-
quences (huscfv) by using pCANTAB5E specific primers
[40]. Bacterial clones carrying huscfv were grown under
IPTG induction for HuScFv expression [40]. The
HuScFv in the E. coli lysates were tested for binding spe-
cificity to rM2 and nM2. Wells of ELISA plate (Costar,
USA) were coated with either rM2 (1 μg in 100 μl of
carbonate-bicarbonate buffer, pH 9.6) or the virus lysate
containing nM2 (5 μg in 100 μl PBS buffer). BSA was
used as control antigen. After blocking the antigen
coated wells with 1% BSA, individual E. coli lysates con-
taining HuScFv were added appropriately to the wells.
Mouse monoclonal anti-E tag was added. Goat anti-
mouse immunoglobulin-horseradish peroxidase (HRP)
conjugate and ABTS substrate were used for color reac-
tion. Antigen coated wells added with lysate of original
HB2151 E. coli and buffer served as background control
and blank, respectively. OD405nm of the content each
well was measured against blank. E. coli clones that the
lysate reacted with the antigen and gave OD405nm above
the background control and two times higher than the
BSA control were selected for further experiment.
Antigenic specificity of the HuScFv in E. coli lysates
were also determined by Western blot analysis. Recom-
binant and native M2 were subjected separately to 14%
SDS-PAGE and the separated components were blotted
onto a nitrocellulose membrane (NC). After blocking
the NC empty sites with 5% skim milk in PBS, the blot-
ted NC was cut vertically into strips. The strips were in-
cubated with the individual E. coli lysates containing
HuScFv at 25°C for 2 h. The unbound materials were re-
moved by washing with PBS containing 0.05% Tween-20
(PBST). The strips were reacted with mouse monoclo-
nal anti-E-tag or mouse polyclonal antibody to rM2
and washed. Goat anti-mouse immunoglobulin-alkalinephosphatase (AP) conjugate and BCIPT/NBT substrate
were used for revealing the antigen-antibody reactive
bands.
Binding of the HuScFv to native M2 in the influenza
virus infected cells were performed. MDCK cells
infected with H5N1 virus at MOI 1 were cultured in a
24 well-plate at 37°C in 5% CO2 atmosphere for 24 h.
The infected cells were washed and permeabilized with
1% Triton-X 100 in PBS for 20 min. After blocking with
3% fetal bovine serum, the permeabilized cells were
added with HuScFv or PAb to M2 and kept at 25°C for
1 h. After washing, mouse monoclonal anti-His tag was
added to the well containing cells that had been exposed
to HuScFv and kept at 25°C for 1 h. Chicken anti-mouse
immunoglobulin-Alexa Fluor® 488 was added to all wells
and kept at 25°C for 1 h. The cells were washed thor-
oughly, mounted and observed under a fluorescence
microscope.
Restriction fragment length polymorphism (RFLP) of
huscfv from individual E. coli clones was determined by
using MvaI restriction enzyme digestion [41]. Digested
DNA preparations were subjected to 14% polyacrylamide
gel electrophoresis and ethidium bromide staining.
Banding patterns of huscfv DNA of all clones were com-
pared [41].
Immunoglobulin frameworks (FRs) and complemen-
tarity determining regions (CDRs) of the deduced amino
acids of huscfv sequences were predicted using the Inter-
national Immunogenetics information system (IMGT/V-
QUEST) [35].
For large scale production of the HuScFv, the huscfv of
E. coli clones of interest were subcloned into pET32c(+)
via restriction endonuclease (HindIII and NotI)
(Fermentas, Lithuania). The recombinant plasmids were
introduced into BL21 (DE3) E. coli. Appropriate trans-
formed E. coli clones were inoculated individually into
250 mL 2 × YT (Yeast Extract Tryptone) broth con-
taining 100 μg/mL ampicillin and induced for HuScFv
expression under 0.5 mM IPTG at 37°C with shaking for
4 h. Bacterial cells were harvested, sonicated in buffer
(50 mM sodium phosphate, 8 M urea, and 300 mM
NaCl, pH 7.0) and centrifuged at 12,000 × g, 4°C, 15
min. HuScFv in each lysate was purified (Talon® metal
affinity resin, Takara, Japan). The HuScFv was dialyzed
against PBS and filtrated through 0.45-μm membrane
(Pall, USA) before use. Reactivity of the purified HuScFv
to rM2 was verified by indirect ELISA and Western blot
analysis using rM2 as the antigen and mouse monoclo-
nal anti-6x-His antibody as the primary antibody for
detecting the 6x-His tagged-HuScFv.
HuScFv mediated interference of virus replication cycle
Influenza viruses were either added directly (experiment
1) or mixed with purified HuScFv (400 ng, ~9.64 × 1012
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before adding (experiment 2) to MDCK cell monolayer
in tissue culture wells (MOI 0.1). Viruses exposed to
rimantadine (0.8 μM, ~4.82 × 1017 molecules) and poly-
clonal antibody to M2 (PAb) (10 μg, ~4 × 1013 mole-
cules) instead of the HuScFv were used as positive
inhibition controls. The viruses in culture medium ser-
ved as negative inhibition or infected cell control. The
plates were incubated in 5% CO2 atmosphere, 37°C, 1 h
to allow the virus entry. Extracellular viruses in each
well were discarded; the cells were rinsed with plain
DMEM and replenished with viral growth medium
[DMEM containing 2% FBS, 2 mM L-glutamine, penicil-
lin (100 U/mL), streptomycin (100 μg/mL)] containing
the respective inhibitors/controls, i.e., 400 ng HuScFv,
10 μg PAb, 0.8 μM rimantadine or medium alone). After
incubation for 15 h, the spent culture fluid of each well
was collected and the cells were washed with PBS and
harvested. Quantitative real-time RT-PCR was used for
enumeration of the viruses in the culture fluids and in-
side the cells. Plaque (foci) assay was also performed for
comparing intracellular viruses among treatments. Three
independent experiments were done.
Quantitative real-time RT PCR (qPCR)
Viral RNA was extracted from 500 μL of each culture
supernatant by using viral nucleic acid extraction kit II
(Geneaid, USA). The RNA was dissolved with 20 μL of
DEPC-treated water. Total RNA was extracted from the
virus infected cells by using total RNA purification kit
(Jena Bioscience, Germany). The amount of total RNA
in each preparation was measured by using NanoDrop
ND-1000 Spectrophotometer (Thermo Scientific, USA)
and kept at −70°C until use. In each qPCR reaction, ei-
ther 2 μL of extracted RNA from the culture super-
natant or 200 ng of total RNA from infected cells were
subjected to viral RNA quantification using 1-step Bril-
liant II SYBR green qRT-PCR master mix kit (Agilent
Technologies, USA). Each PCR master mix (12.5 μL)
was prepared on ice with 2 × Brilliant II SYBR® Green
QRT-PCR Master Mix, RT/RNase block enzyme, 200
nM of each primer specific to gene sequence coding for
influenza A virus M1: forward 5′-CTTCTAACCGAG
GTCGAATCGTA-3′ and reverse 5′-TCCATGAGA
GCCTCGAGAT-3′, and RNA template. PCR was per-
formed using Mx 3000PTM instrument (Stratagene,
USA). The qPCR condition was: reverse transcription at
42°C for 1 h, initial denaturation at 95°C for 10 min and
40 cycles at 95°C for 1 min, 58°C for 1 min and 72°C for
1 min. The thermal profile used for dissociation curve
analysis was: 95°C for 1 min then ramped down to 55°C
(0.5°C/s) and ramped up to 95°C. A standard curve was
constructed from Ct of ten-fold dilutions of the pET20b
(+) carrying gene sequence coding for M1 (ranged from1000 to 1 ng or 2.07 × 1011 to 2.07 × 108 copies). Ct of
each sample was expressed as log2 of RNA copies calcu-
lated from the standard curve.
Plaque assay
Influenza virus plaques (foci) in the infected cells were
revealed as described previously [42]. Infected cells in
each tissue culture well were washed with PBS, fixed
with cold absolute methanol at 25°C, 1 h, washed again,
and permeabilized by using 0.3% Triton X-100 in PBS
for 20 min. The cells were blocked by incubating with
3% FBS at 25°C, 1 h. After washing, mouse PAb to rNP
(1:1,000) was added and incubated at 25°C, 1 h. Goat
anti-mouse-AP (1:3,000) was added, incubated at 25°C
for 1 h and the cells were equilibrated in 0.15 M Tris–
HCl, pH 9.6, at 25°C for 15 min before adding with
BCIP/NBT substrate for color development. When the
purple foci appeared under inverted microscope the re-
action was stopped by rinsing with distilled water. The
foci in the MDCK cell monolayer were observed and
counted under a light microscope.
Phage mimotopes, HuScFv epitopes and validation of the
phage mimotope
Ph.D.-12™ phage display peptide library (New England
Biolabs, USA) was used to determine HuScFv bound
phage mimotopes as described previously [41]. Mimo-
tope peptide sequences were deduced from the phage
DNA sequences by DNAMAN software version 4.15.
The mimotopes were classified into mimotope types by
using Phylogeny ClustalW [43] The sequences of each
mimotope type was multiply aligned by Kalign with M2
linear sequences of drug sensitive and resistant A/H5N1
viruses (Accession numbers AY651385.1 for clade 1 and
AB478035.1 for clade 2) for identification of M2 residues
bound by the HuScFv (epitopes) [35].
Phage clones displaying the mimotopes were tested in
competitive ELISA for determining their capacity in
blocking the binding HuScFv to rM2 as described previ-
ously [35]. Mimotopic phages were propagated in
ER2738 E. coli and the titers of the amplified phages
were determined according to manufacturer’s instruction
(New England Biolabs, USA). Various amounts (104, 105
and 106 plaque forming unit; pfu) of the phages (50 μl)
were mixed individually with fixed amount of HuScFv (5
μg in 50 μl) and incubated at 37°C for 1 h. The HuScFv
mixed with irrelevant phage mimotope served as back-
ground inhibition controls and HuScFv in buffer were
negative inhibition controls (maximum binding, 100%).
After adding individual mixtures to the rM2 coated
wells and incubated, all wells were washed and mouse
monoclonal anti-E tag antibody, goat anti-mouse im-
munoglobulin-HRP conjugate and ABTS substrate
were added, respectively, with washing between steps.
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against the background binding controls. The % ELISA in-
hibition was calculated:
% ELISA inhibition ¼ OD405nmof maximum binding−OD405nmof testð Þ
OD405nmmaximum bindingð Þ
 
Homology modelling and molecular docking to
determine the regions and residues of tetrameric M2 ion
channel bound by the HuScFv
Amino acid sequences similar to the rM2 and the
HuScFv were identified by using a Discovery studio (DS)
database. Three dimensional (3D) structures of the se-
quences that provided maximum identities were used as
templates for homology modelling. The modelled struc-
tures were validated by PROCHECK analysis [44]. Com-
plex structures between the modelled rM2 and HuScFv
were predicted by using rigid bodies docking technique.
The ZDOCK and RDOCK modules embedded on Dis-
covery Studio program were used as tools for docking
calculation and structural refinement, respectively. The
modelled M2 was set as input receptor and the HuScFv
as ligands. The dock complexes with the lowest RDOCK
energy were determined for identification of the regions
and residues of the tetrameric M2 ion channel in-
teracting with the HuScFv.
Multiple alignments of M2 sequences of various influenza
A subtypes and H5N1 clades
The amino acid sequences of influenza A viruses includ-
ing H1N1, H3N2, H5N1 (clades 0, 1, 2 and 7 which in-
fect humans), H7N3, H7N9 and H9N2 were retrieved
from the NCBI database (http://www.ncbi.nlm.nih.gov/
protein). For the multiple sequence alignments, the pro-
gram MAFFT version 7 was used. The alignments were
verified following the algorithm of semi-homology. The
verification concerned the possible genetic relationship
between compared positions which were possible re-
placements by single transition/transversion.
Statistical analysis
Means and standard deviations (SD) of log2 of M1
mRNA derived from triplicate cell culture wells of three
independent experiments were used for comparison
between tests and controls. P value < 0.05 of unpaired
t-test was significantly different.
Additional files
Additional file 1: Figure S1. Binding of HuScFv of clones no. 2, 19,
23 and 27 and PAb to M2 in the MDCK cells infected with amantadine
sensitive (NP-172) (blocks of middle column, respectively ) and resistant
(KU08) (blocks of right column, respectively) H5N1 viruses. Non-infected
cells reacted with HuScFv and PAb are shown in respective blocks of the
left column.Additional file 2: Figure S2. Appearances of influenza virus foci in
infected MDCK cells treated with HuScFv, PAb to M2 and rimantadine.
Adamantane sensitive [A/chicken/Thailand/NP-172/2006 (H5N1 clade 2)]
and resistant [A/dog/Thailand/KU-08/2004 (H5N1 clade 1) viruses were
incubated with M2 specific-HuScFv before adding to MDCK cell
monolayer. Viruses mixed with rimantadine and PAb to M2 were used as
positive inhibition controls while viruses in culture medium served as
negative inhibition (infected cell) controls. The cells were cultured in the
medium containing respective HuScFv, rimantadine, PAb to M2 and
medium alone for 15 h. Extracellular viruses were removed and the cells
were washed before subjecting to immune-staining for virus plaques
(foci). A and I: Uninfected MDCK cell monolayer; B and J: negative
inhibition controls (MDCK cells infected with the viruses); C and K: MDCK
cells infected with viruses exposed to PAb to M2; D and L: MDCK cells
infected with rimantadine exposed viruses; E and M, F and N, G and O
and H and P: MDCK cells infected with viruses exposed to HuScFv2,
HuScFv19, HuScFv23 and HuScFv27, respectively.
Additional file 3: Figure S3. Multiple alignments of the M2 amino acid
sequences of various influenza A subtypes and clades of subtype H5N1.
The peptides of M2 proteins which were binding sites of the HuScFv of
clones no. 2, 19, 23 and 27 are highly conserved across A subtypes and
H5N1 clades.
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